#levodopa market size

[govindtbrc]

Levodopa Market: Key Trends and Developments in Parkinson’s Disease Treatment up to 2033

Market Definition The Levodopa Market centers around the production and distribution of levodopa, a critical medication used primarily for the treatment of Parkinson’s disease and dopamine-responsive dystonia. As the gold-standard treatment for Parkinson’s disease, levodopa works by converting to dopamine in the brain, replenishing the neurotransmitter that becomes deficient in patients suffering from this degenerative neurological disorder. Available in various formulations, including oral tablets, capsules, and combination drugs (such as carbidopa-levodopa), levodopa remains a vital therapeutic option.

To Know More @ https://www.globalinsightservices.com/reports/levodopa-market

The global Levodopa market is anticipated to expand from $4.2 billion in 2023 to $7.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.8%.

Market Outlook The Levodopa Market is poised for steady growth, driven by the increasing prevalence of Parkinson’s disease worldwide and the ongoing demand for effective treatments. The aging global population is a significant factor contributing to the rising incidence of Parkinson’s, as the disease is more common among older adults. As awareness of neurological disorders improves and diagnostic capabilities advance, more patients are being identified, further boosting the demand for levodopa-based therapies.

A key trend in the market is the development of new formulations and delivery methods aimed at enhancing the efficacy and patient adherence of levodopa treatment. Continuous research is underway to optimize the absorption and bioavailability of levodopa, as well as to reduce its side effects, such as motor fluctuations and dyskinesia. Innovative delivery systems, such as intestinal gel formulations and extended-release capsules, are being explored to provide more consistent symptom control.

Pharmaceutical companies are also investing in combination therapies that incorporate levodopa with other drugs to improve therapeutic outcomes. For example, adding enzyme inhibitors like entacapone or carbidopa helps to prevent the breakdown of levodopa before it reaches the brain, enhancing its effectiveness and reducing the required dosage. These advancements are crucial in improving the quality of life for Parkinson’s patients, who often experience a decline in treatment efficacy over time.

However, the market faces challenges related to the side effects and long-term complications of levodopa therapy. The development of motor complications, such as dyskinesia and the “on-off” phenomenon, remains a concern, prompting ongoing research into alternative treatment strategies and adjunctive therapies. Additionally, the high cost of advanced levodopa formulations can be a barrier for patients in low- and middle-income countries, where access to quality healthcare remains limited.

Request the sample copy of report @ https://www.globalinsightservices.com/request-sample/GIS32379

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request For Report Customization @ https://www.globalinsightservices.com/request-customization/GIS32379

Market Segmentation

In 2023, the Levodopa market volume was estimated at 320 million units, with projections to reach 500 million units by 2033. The oral administration segment dominates the market, holding a 55% share, while the injectable segment follows with 30%. The transdermal segment, although smaller at 15%, is experiencing rapid growth due to advancements in drug delivery systems. The demand for Levodopa is primarily driven by its effectiveness in managing Parkinson’s disease symptoms, with North America and Europe being the largest consumers due to high prevalence rates and advanced healthcare infrastructure.

Competitive dynamics are heavily influenced by key players such as AbbVie Inc., Merck & Co., and Teva Pharmaceutical Industries. These companies leverage strategic collaborations and R&D investments to maintain market leadership. Regulatory frameworks, particularly those by the FDA and EMA, significantly impact market strategies, focusing on drug safety and efficacy. Future projections indicate a 10% annual growth rate, driven by an aging population and increased awareness of neurological disorders. However, stringent regulations and high R&D costs remain challenges. The integration of AI in drug development and personalized medicine approaches is expected to offer new growth opportunities in the Levodopa market.

Major Players

Mylan

Teva Pharmaceutical Industries

Sun Pharmaceutical Industries

Cipla

Zydus Cadila

Aurobindo Pharma

Torrent Pharmaceuticals

Alkem Laboratories

Lupin Pharmaceuticals

Dr Reddy’s Laboratories

Wockhardt

Intas Pharmaceuticals

Glenmark Pharmaceuticals

Hikma Pharmaceuticals

Apotex

Amneal Pharmaceuticals

Endo International

Perrigo Company

Mallinckrodt Pharmaceuticals

Lannett Company

Request For Discounted Pricing @ https://www.globalinsightservices.com/request-special-pricing/GIS32379

Research Scope

Scope �� Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis

For In-Depth Competitive Analysis, Buy Now @ https://www.globalinsightservices.com/checkout/single_user/GIS32379

About Us

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[dtgmarketreport]

Parkinson’s Disease Treatment market  Size, Share, Trends & Forecast 2025-2035

Parkinson's Disease Treatment Market Overview

The Parkinson’s Disease Treatment market was valued at USD 6.4 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.2%, reaching USD 18.6 billion by 2035. This market includes medications such as dopaminergic drugs (e.g., levodopa), non-dopaminergic therapies, surgical treatments like deep brain stimulation, and supportive therapies. Growth is driven by rising disease prevalence, advancements in treatment technologies, and increased diagnostic rates.

Key Market Insights ·Largest Market: North America leads due to advanced treatments and robust R&D investments. ·Fastest Growing Region: Europe, supported by healthcare spending and aging demographics.

·Major Segments: oTreatment Type: Non-surgical treatments dominate, with oral medications being preferred for their convenience and lower cost.

oRoute of Administration: Oral drugs, such as levodopa, are the most popular. ·Challenges: Despite progress, most treatments focus on symptom management rather than a cure, limiting long-term growth. High treatment costs further strain healthcare systems, particularly in developing countries.

Market Dynamics Drivers: oExpanding healthcare infrastructure and rising awareness of Parkinson’s disease. oIncreased R&D investments in innovative therapies, including neuroprotective agents and personalized medicine. oIntegration of digital health solutions like telemedicine and mobile apps to improve patient care. Opportunities: oBiomarker development enables early diagnosis and personalized treatments, improving patient outcomes. oPatient-centric approaches based on genetic data are driving innovation, enhancing treatment effectiveness and reducing side effects. Restraints: oLack of curative therapies limits market potential. oThe diversity in symptoms and progression rates complicates treatment standardization. Competitive Landscape Leading companies like AbbVie, Teva Pharmaceuticals, and Lundbeck are investing in novel therapies. For instance, AbbVie’s Tavapadon showed promising results in Phase 3 trials as a Parkinson’s monotherapy. Medtronic’s ADAPT-PD clinical trial is setting new benchmarks in neuromodulation research. Collaborations, such as Roche’s partnerships with biotech firms, highlight the industry’s focus on innovation. Regional Trends ·North America: Advanced drug formulations and neuromodulation technologies drive market dominance. ·Europe: Government-backed R&D and increasing adoption of personalized care models propel growth. ·Asia-Pacific: Rising healthcare expenditure and aging populations are boosting demand for treatments. Conclusion The Parkinson’s Disease Treatment market shows promising growth fueled by technological advancements, personalized medicine, and global advocacy for improved care solutions. However, addressing challenges like symptom-focused therapies and high costs will be essential for sustained growth. Get sample report for more detailed insights https://www.metatechinsights.com/request-sample/1176

[hello-delveinsight]

DelveInsight's Comprehensive Insights into Parkinson's Disease Market Dynamics

DelveInsight's Parkinson's Disease Market Insights report offers a thorough understanding of current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted market size from 2019 to 2032. The report provides segmentation for 7MM (the United States, the EU-4 - Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Click here to know Parkinson’s Disease Market

Key Takeaways from the Parkinson's Disease Market Report:

Parkinson's Disease Market Size and Prevalence:

The Parkinson's disease market size in the 7MM was approximately USD 3.2 billion in 2022.

Estimated total diagnosed prevalent Parkinson's disease cases in the 7MM were around 2.5 million in 2022.

Leading Parkinson's Disease Companies and Drug Development:

Key industry leaders, including Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, and others, are actively developing novel Parkinson's disease drugs.

Promising therapies in the pipeline include Tavapadon, P2B001, ABBV-951 (foscarbidopa/foslevodopa), BIIB122/DNL151, and more.

Parkinson's Disease Epidemiological Segmentation:

DelveInsight estimates approximately 2.5 million diagnosed prevalent cases of Parkinson's disease in the 7MM in 2022.

Parkinson's disease is identified as a male-dominant disease, with 54% of cases in males and 46% in females in the 7MM.

Click here to know Parkinson’s Disease Market

Parkinson's Disease Overview:

Parkinson's disease is a degenerative ailment characterized by the loss of nerve cells in the substantia nigra, a brain region governing movement. The exact cause remains unknown, but a combination of genetic and environmental factors is suspected. Motor symptoms such as bradykinesia, stiffness, rest tremor, and postural instability are common, accompanied by non-motor symptoms impacting a patient's quality of life.

Parkinson's Disease Epidemiological Segmentation:

The Parkinson's disease market report offers epidemiological analysis for the study period 2019–2032, segmented into diagnosed prevalent population, gender-specific diagnosed prevalent population, age-specific diagnosed prevalent population, and stage-specific diagnosed prevalent population.

Parkinson's Disease Treatment Landscape:

The Parkinson's Disease treatment landscape involves various drugs, with Levodopa being the gold standard for managing motor problems. Medications such as levodopa, dopamine agonists, MAO B inhibitors, catechol o-methyltransferase inhibitors, and others aim to reduce motor symptoms. INBRIJA (levodopa) is a notable inhalation therapy supplementing daily carbidopa-levodopa medications to alleviate "off-episodes" and motor symptoms.

Pipeline Parkinson's Disease Therapies and Key Companies:

The pipeline includes potential therapies like Tavapadon, P2B001, ABBV-951, BIIB122/DNL151, and others developed by leading companies such as Cerevel Therapeutics, Pfizer, AbbVie, Biogen, and more.

Parkinson's Disease Market Dynamics:

The Parkinson's disease market is anticipated to evolve, driven by research and development efforts, emerging therapies, and improvements in diagnosis rates. However, challenges such as the absence of a cure, symptomatic treatments, side effects, and undetected cases may impede growth. The robust pipeline and advancements in disease-modifying treatments offer optimism for the future.

In conclusion, DelveInsight's Parkinson's Disease Market Insights report provides a comprehensive understanding of the current landscape, promising therapies, and challenges, guiding stakeholders in making informed decisions.

Click here to know Parkinson’s Disease Market

Trending Reports:

Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market

Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market

Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market

Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market

Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market

Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market

Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market

Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight

Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market

Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market

Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market

Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market

Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market

Eczema Market: https://www.delveinsight.com/report-store/eczema-market

Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market

Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market

Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market

Healthcare Consulting Service

DelveInsights multidimensional, purposeful, and credible pharma and medtech consulting services will aid in the acceleration of product services, including aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, and diagnostic landscape assessment to overcome several market challenges.

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Contact Us:

Ankit Nigam

Assistant Manager Marketing

info@delveinsight.com

+91-9650213330

[reportsneww]

Ataxia Diagnosis and Treatment Market size 2023 to 2031

Newark, New Castle, USA - Growth Plus Reports' most recent study examines the Global Ataxia Diagnosis and Treatment Market's production, prospective uses, demand, key companies, and SWOT analysis.

The Ataxia Diagnosis and Treatment Market Report will help you determine the best distribution strategies for specific products and identify potential markets. In addition, the report examines the purchasing and supply patterns that impact the market. The Ataxia Diagnosis and Treatment market research report provides insights into the limitations, market trends, prospects, drivers, and competition in the Ataxia Diagnosis and Treatment sector.

You may get insights into the TOC, and Statistics for essential facts, information, trends, and competitive landscape information.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/ataxia-diagnosis-and-treatment-market/8219

The following are the leading companies in the Global Ataxia Diagnosis and Treatment market:

CRISPR Therapeutics AG

Bio-Techne Corporation

Cellectis SA

Eli Lilly & Company

GlaxoSmithKline Plc

Larimar Therapeutics, Inc.

Capsida Biotherapeutics, Inc.

Intellia Therapeutics, Inc.

Bluebird bio, Inc.

AAVLife SAS

Editas Medicine, Inc.

Healx

Acorda Therapeutics, Inc.

Lundbeck A/S

Growth Plus Reports studies the key trends in each category and sub-segment of the Ataxia Diagnosis and Treatment market, along with Global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

SEGMENTATION

GLOBAL ATAXIA DIAGNOSIS AND TREATMENT MARKET - ANALYSIS & FORECAST, BY TYPE

Diagnosis

Brain Scans

Genetic Testing

Lumbar Puncture

Others

Treatment

Levodopa

Pramipexole

Venlafaxine

Others

GLOBAL ATAXIA DIAGNOSIS AND TREATMENT MARKET - ANALYSIS & FORECAST, by Indication

Friedreich's Ataxia

Episodic Ataxia

Ataxia-Telangiectasia

Spinocerebellar Ataxia

Others

For More Information or Query or Customization visit: https://www.growthplusreports.com/inquiry/customization/ataxia-diagnosis-and-treatment-market/8219

Companies may utilize Ataxia Diagnosis and Treatment market report to get insights on market variables and any restraints that may affect the manufacturing of their product. Companies that are expanding abroad require thorough Global market research that includes real market data to assist with their marketing strategy. This Global market Ataxia Diagnosis and Treatment industry study analyzes important market dynamics and provides in-depth information and statistics to help companies flourish. This research report on the Ataxia Diagnosis and Treatment market takes advantage of advanced and professional approaches such as SWOT analysis and GRG Health's unique GrowthMIX strategy.

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Ataxia Diagnosis and Treatment Market TOC: https://www.growthplusreports.com/report/toc/ataxia-diagnosis-and-treatment-market/8219

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

[neha24blog]

Parkinson’s Disease Treatment Market Focusing On The Basis Of Drug Class, Distribution Channel, Region And Forecast 2030 : Grand View Research Inc.

Parkinson’s Disease Treatment Market Focusing On The Basis Of Drug Class, Distribution Channel, Region And Forecast 2030 : Grand View Research Inc.

San Francisco, 29 Dec 2022: The Report Parkinson’s Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class (Carbidopa-levodopa, Anticholinergics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2022 – 2030 The global Parkinson’s disease treatment market size is expected to reach USD 11.98 billion by 2030, according to a new…

[jesse-pinkman123]

The report contains proven analysis by regions. It reduces the risks involved in making opinions as well as strategies for companies and individualities interested in the request.

[myabhijitr]

Levodopa Market - Size, Share, Outlook, and Analysis by 2018-2026

Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.

Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.

Get Request sample copy for Industry Insight: https://www.coherentmarketinsights.com/insight/request-sample/2247

Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.

Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.

North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2247

Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.

The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.

[expertofmarketinsights-blog]

Levodopa Market Positive Long-Term Growth Outlook 2018-2026

Levodopa or L-Dopa is a chemical building-block that converts into a dopamine in body. Dopamine is the chemical messenger released in brain. It mediates pleasure, cognition, and memory functions. Nearly all patients receive the dopamine precursor levodopa, which adequately control symptoms of Parkinson's disease (PD) at early stage of the disease. Carbidopa is often included with levodopa-containing drugs in order to boost its efficacy by slowing down the metabolism of dopamine. Click To Read More On Levodopa Market

Levodopa Market Driver

Development of novel formulations and efficient drug delivery methods for levodopa are expected to drive growth of the levodopa market. For instance, a clinical study for gastric retentive Accordion Pill, an immediate drug release formulation by Intec Pharma Ltd., is ongoing in clinical phase III and is expected to complete in September 2018. Accordion Pill is a Carbidopa/Levodopa (AP-CD/LD) combinational oral drug delivery system, which is designed to improve the efficacy and safety of existing CD/LD drugs by utilizing an efficient gastric retention and specific release mechanism.

Moreover, Impel NeuroPharma Inc. is conducting phase II clinical study for INP103, a drug-device combination product containing a drug component, L-dopa, and device component I231 Precision Olfactory Delivery (POD) device. The study is expected to complete in November 2018.

Furthermore, advancement in diagnosis of Parkinson's disease (PD) progression is expected to boost growth of levodopa market. For instance, a clinical study conducted by Washington University School of Medicine, for measuring PD progression both by using Magnetic Resonance Imaging (MRI) and by controlled dose of levodopa for discovering suitable biomarker of PD is currently in clinical phase I and is expected to complete in February 2019.

Levodopa Market Restraint

Shortage of drug supply in the market due to delay in manufacturing and supply of levodopa is expected to hamper levodopa market growth. For instance, Merck Sharp & Dohme Ireland (Human Health) Ltd. in September 2018, anticipated stock shortage of some Sinemet (Carbidopa/ Levodopa) products in the Irish market in near future due to global manufacturing delays in production and demand for resupply of these products.

Competitive Landscape

The key players operating in levodopa market include, Taj Pharmaceuticals Limited., Guangzhou HanFang Pharmaceutical Company Limited, Poulvet.com, Teva Pharmaceutical Industries Ltd., UBM, Zhejiang Wild Wind Pharmaceutical Co., Ltd., and SWAPNROOP.

Levodopa Market – Regional Analysis

On the basis of region, the global levodopa market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to dominate the global levodopa market, owing to approval of new products by the U.S. Food and Drug Administration (FDA). For instance, in 2015, FDA approved an extended-release oral formulation of Levodopa/Carbidopa called Duopa, manufactured by AbbVie Inc., in the U.S. market. Duopa is a gel formulation of Carbidopa/Levodopa enteral suspension and is administered using a small, portable infusion pump that delivers Carbidopa and Levodopa directly into the small intestine, which continuously release over 16 hours in the body.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2247

Europe region is expected to witness significant growth in levodopa market due to involvement of key players for marketing novel formulations in European region. For instance, Acorda Therapeutics, Inc., in March 2018, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods (OFF symptoms implies recurrence of symptoms such as rigidity, and tremors after long period of levodopa use) in people with PD taking a Carbidopa/Levodopa regimen.

Furthermore, in November 2015, Impax Laboratories, Inc. received European Commission (EC) marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease in Europe region.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[vijayanger12]

A recent report provides crucial insights along with application based and forecast information in the Global Levodopa and Benserazide Hydrochloride Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Levodopa and Benserazide Hydrochloride market.

[marketreports3]

Research On World Levodopa Market Report 2025

Report on World Levodopa Market by Product Type, Market, Players and Regions-Forecast to 2025 by DecisionDatabases.com

Levodopa market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.

The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.

The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry Players.

Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/49427-world-levodopa-market-report

The Players mentioned in our report

Teva Pharmaceutical

Taj Pharmaceuticals

Guangxi Hefeng Pharmaceutical

Shandong Xinhua Pharmaceutical

Wild Wind (Group)

Shanghai Chematis

SWAPNROOP

Global Levodopa Market: Application Segment Analysis

Global Levodopa Market: Regional Segment Analysis

USA

Europe

Japan

China

India

South East Asia

Download Free Sample Report of World Levodopa Market @ https://www.decisiondatabases.com/contact/download-sample-49427

There are 10 Chapters to Deeply Display the World Levodopa Market. Chapter 1 About the Levodopa Industry Chapter 2 World Market Competition Landscape Chapter 3 World Levodopa Market share Chapter 4 Supply Chain Analysis Chapter 5 Company Profiles Chapter 6 Globalisation & Trade Chapter 7 Distributors and Customers Chapter 8 Import, Export, Consumption and Consumption Value by Major Countries Chapter 9 World Levodopa Market Forecast through 2025 Chapter 10 Key success factors and Market Overview

Purchase the complete World Levodopa Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-49427

Other Reports by DecisionDatabases.com:

World Levofloxacin Market Research Report 2025 (covering USA, Europe, China, Japan, India, South East Asia and etc)

World Melamine Powder Market Research Report 2025 (covering USA, Europe, China, Japan, India, South East Asia and etc)

About-Us: DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.

Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 9028057900 Web: https://www.decisiondatabases.com/

[eretzyisrael]

TEL AVIV (Reuters) - Israel’s Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson’s disease, expects to start earning money from the program sometime in 2019.

Jeffrey Meckler, chief executive of Israel's Intec Pharma holds up their long-lasting pill to treat Parkinson's disease, during an interview with Reuters in Tel Aviv, Israel November 7, 2018. REUTERS/Steven Scheer

Intec recently completed enrolling 462 patients for a Phase III trial for the pill that opens up like an accordion, with the levodopa drug remaining in the stomach for 8-12 hours, requiring fewer doses a day. Results are expected in mid-2019.

The Phase II trial showed a 45 percent reduction in “daily off time,” which gave patients more than two extra hours a day of movement.

“I feel very comfortable that we have an approvable program here. I would like to see as big an effect size as possible, but there is commercial viability at any effect size,” Jeffrey Meckler, Intec’s chief executive, told Reuters after a news conference on Wednesday.

“I hope next year we will be able to monetize value out of the Parkinson’s program, whether that is the sale of the company, sale of the program or a license partnership,” said Meckler, who took over in July 2017.

He said a large number of Parkinson’s companies were interested in the program but he declined to elaborate.

Assuming a 10 percent market share, Meckler said: “We have a drug that is worth more than $300 million a year.”

The drug would likely compete with Amneal Pharmaceuticals’ Rytary, which also reduces the amount of off-time.

Intec is also looking at a pill-based delivery for medical cannabis and has begun early stage trials.

“The cannabinoid program has much bigger potential than Parkinson’s,” Meckler said, adding the company aimed to license out drug delivery of medical cannabis prior to Phase III trials.

Intec’s strategy is to look for existing drugs and put them into its delivery platform, in which medicine is folded up in a film with layers that opens like an accordion.

Intec is working on trying to adapt its platform for an undisclosed drug from Novartis and a decision is expected on its viability in early 2019, said Meckler.

The Nasdaq-listed company raised $35 million in the second quarter, helping to fund the Parkinson’s trial. While not yet profitable, Intec had $66 million in cash at the end of June and is burning about $10 million a quarter.

“We don’t expect to raise money again before the Parkinson’s data” next year, Meckler said.

Reporting by Steven Scheer; Editing by Mark Potter

Our Standards:

The Thomson Reuters Trust Principles.

[market-insider]

Drug Device Combination Products Market Driven By Rising Demand For Minimally Invasive Techniques

The global drug device combination products market size is expected to reach USD 251.9 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.8% from 2022 to 2030. The rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices. 

Gain deeper insights on the market and receive your free copy with TOC now @: Drug Device Combination Products Market Report

The increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to building a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in the future and boost overall growth during the forecast period. 

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce the need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in the case of drug-device combination products. 

[globalmarketsresearchreports]

Global Anti-Parkinson Drugs Market Competitive Strategies and Forecasts to 2031

The Anti-Parkinson Drugs Global Market Report 2021-31 by The Business Research Company describes and explains the global anti-Parkinson drugs market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

The Anti-Parkinson Drugs Global Market Report 2022 covers anti-Parkinson drugs market drivers, anti-Parkinson drugs market trends, anti-Parkinson drugs market segments, anti-Parkinson drugs market growth rate, anti-Parkinson drugs market major players, and anti-Parkinson drugs market size.

View Complete Report:

The anti-Parkinson drugs market report provides in-depth analysis of the impact of COVID-19 on the global anti-Parkinson drugs industry along with revised market numbers due to the effects of the coronavirus and the expected anti-Parkinson drugs market growth numbers for 2022-2031.

The global anti-Parkinson’s drugs market size is expected to grow from $8.86 billion in 2021 to $9.56 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-Parkinson drugs market share is expected to reach $12.25 billion in 2026 at a CAGR of 6.4%.

Request Report Sample Now: https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Anti-Parkinson Drugs Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.

TBRC’s report covers the anti-Parkinson drugs market segments- 1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Others

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Table Of Contents

1. Executive Summary

2. Anti-Parkinson Drugs Market Characteristics

3. Anti-Parkinson Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Anti-Parkinson Drugs

5. Anti-Parkinson Drugs Market Size And Growth

.

.

27. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles

28. Anti-Parkinson Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market

30. Anti-Parkinson Drugs Market Future Outlook and Potential Analysis

31. Appendix

About The Business Research Company:  The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.  

Contact Information:  The Business Research Company  Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Find us on

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany/

Blog: http://blog.tbrc.info/

[mrfrblogresearch02]

Parkinson's Disease Therapeutics Market New Developments: Current Industry Trends, witness Highest Growing CAGR, and Upcoming Technologies 2027

Market Overview:

The recent report by Market Research Future (MRFR) asserts that the global Parkinson’s Disease Therapeutics market 2020 is slated to acquire a substantial market valuation at a moderate CAGR over the review period.

Global Parkinson’s Disease Therapeutics Market is anticipated to witness significant growth, owing to the increasing cases of Parkinson’s disease, with the growth in aging population levels. Furthermore, increasing environmental factors & genetic heredity is augmenting the growth of Parkinson’s disease therapeutics market. Therefore, it may drastically result in expanding the market size during the forecast period. Pharmaceutical firms are creating new and improved therapies for Parkinson's disease (PD), and lately, there have been some significant product launches in Parkinson's disease therapeutics and other assistive therapeutics. Additionally, most of the global firms have a healthy drug pipeline for the treatment of Parkinson's disease, and as per the estimations, the forecast period may observe the launch of a few blockbuster drugs.

Additionally, the Parkinson's Disease Therapies Market Size is growing due to rising environmental variables and genetic heredity. However, the risk of Parkinson's disease rises with age, and the disease occurs most frequently in people over 50.

Segmental Analysis

The global Parkinson’s disease therapeutics market is analyzed on the basis of type, treatment, and end-user.

The global Parkinson’s disease therapeutics market, based on the treatment type, is bifurcated into medication and surgical therapy. The medication segment is segmented further into COMT inhibitors, peripheral decarboxylase inhibitors, MAO inhibitors, dopamine precursors, and others. Surgery therapy is further bifurcated into deep brain stimulation (DBS) and carbidopa/levodopa enteral suspension.

On the basis of end-user, the Parkinson’s Disease Therapeutics market is categorized into hospitals & clinics, academic & industrial research, and others.

Detailed Regional Analysis The geographical analysis of the Global new parkinson drug has been conducted in four major regions, namely the Asia Pacific, Europe, North America, Latin America, and the Middle East and Africa.

Parkinson’s disease therapeutics market is led by North America owing to the rising healthcare spending that contributes to improving the market growth in this region. The total number of Parkinson’s disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Additionally, the high cost of Parkinson's disease therapeutics in the United States also leads to significant market size in terms of revenue.

It is projected that Europe stands second in the global Parkinson’s disease therapeutics market. The increasing government initiatives to promote the healthcare sector and augmented adoption of research and development projects for chronic diseases in the healthcare domain fuel the market in this region. Moreover, the entry of market players into strategic partnerships and collaborations with the chemical industry drives the growth of the market in Europe.

The Asia Pacific is likely to observe growth in the Parkinson’s disease therapeutics market during the review period due to the rising number of healthcare organizations, growing prevalence of Parkinson’s disease. Moreover, the growing incidence of the geriatric population in the region influence market growth. India, China, and Japan are the key market players in this region, and the Asia Pacific is valued to be the fastest-growing market for Parkinson’s disease therapeutics.

The Middle East and Africa hold the least share in the global Parkinson’s disease therapeutics market due to the incidence of stringent government policies and weak economies.

Competitive Analysis:

Salix Pharmaceuticals

GlaxoSmithKline Plc

Impax Laboratories, LLC

Teva Pharmaceutical Industries Ltd

Novartis AG, Orion Corporation

Mylan N.V.

Par Pharmaceutical

Cipla Inc.

Daiichi Sankyo

Apotex Inc.

Wockhardt Limited

The important contenders in the Parkinson's disease therapeutics market are GlaxoSmithKline Plc, Novartis AG, Impax Laboratories, LLC, Salix Pharmaceuticals, Apotex Inc., Teva Pharmaceutical Industries Ltd, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, and Wockhardt Limited.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[ddnewmarketthreads]

Parkinson’s Disease Market Size, Share, Growth Opportunity and Trends by Growing CAGR till 2028

The Global Parkinson’s Disease Market size and analysis covered in the latest DecisionDatabases.com report titled “Global Parkinson’s Disease Market 2022 by Manufacturers, Regions, Type, and Application, Forecast to 2028” provides a holistic understanding about the market. The systematic and insightful flow of information bifurcated into 15 chapters will surely enhance the reader’s understanding of the market dynamics, key player profiles, market share, and forecast till the year 2028. The report’s coverage of worldwide industry size and revenue aids in comprehending the market’s impact study. The study is expected to forecast the market’s future potential, allowing better decisions to be made.

Access FREE Sample Copy of the Parkinson’s Disease Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-35908

Global Parkinson’s Disease Market Segmentation By Type:

Carbidopa/Levodopa

Dopamine Receptor Agonists

MAO-Inhibitors

Global Parkinson’s Disease Market Segmentation By Applications:

Hospitals

Clinics

Global Parkinson’s Disease Market Segmentation By Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia & Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa & Rest of MEA)

Global Parkinson’s Disease Market Players Profiled in the report (can be customized):

Teva

Novartis

GSK

AbbVie

Merck

Boehringer Ingelheim

Impax

Lundbeck

Sun Pharma

Wockhardt

UCB

Valeant Pharmaceuticals

Others

The Global Parkinson’s Disease Market Report includes market data for the years 2017 to 2027. The research provides an overview of the market, including key drivers and risk factors. It also assesses the competitive landscape of the major players. The research is expanded to include regional market statistics as well as type and application information. From 2021 through 2026, the research anticipates sales and revenue. The report also goes over the sales route in detail.

Do You Have Any Query Or Report Customization? Ask Our Market Expert @ https://www.decisiondatabases.com/contact/ask-questions-35908

Parkinson’s Disease Market Report Scope –

Report AttributeDetailsBase Year2021Estimated Year2022Historical Years Covered2017 – 2021Forecast Period2023 – 2028Quantitative unitsRevenue (USD Million) or/and Volume and CAGR from 2022 to 2028Segments CoveredTypes, Applications, and more.Report CoverageRevenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and TrendsRegional ScopeNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

The report covers answers for the below questions –

What is the future scope of the Parkinson’s Disease market?

What is the anticipated growth of the Parkinson’s Disease market in the next six years?

Which region/ country will register the highest growth in the Parkinson’s Disease market in the coming years?

What are the Parkinson’s Disease market opportunities, its driving forces, and market risks?

Which are the sales/revenue/global market share of key Parkinson’s Disease manufacturers since the last two years?

What is the Parkinson’s Disease competitive situation in terms of sales, revenue, and global market share of top Parkinson’s Disease manufacturers?

What are the Parkinson’s Disease Industry sales, revenue, and growth data for North America, Europe, Asia Pacific, Latin America, and Middle-East and Africa?

What are the sales and revenue data by type and application, with sales market share and growth rate by type, application for the year 2017-2021?

What are the sales and revenue forecast data by type and application for the year 2022-2028?

What are the prominent Parkinson’s Disease sales channel, distributors, and customers?

Directly Purchase the Complete Global Parkinson’s Disease Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-35908

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map clients’ research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 90 28 057900 Visit Website || Official Blog || Insights Analysis